|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Celgene Corporation |
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00496444 |
Primary Objective:
1. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in patients with advanced cancer.
Secondary Objectives:
Condition | Intervention | Phase |
Advanced Cancers |
Drug: Azacitidine Drug: Valproic acid |
Phase I |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Azacitidine Divalproex sodium Valproate Sodium Valproic acid |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I Study of Low-Dose Hypomethylating Agent Azacitidine Combined With the Histone Deacetylase Inhibitor Valproic Acid in Patients With Advanced Cancers |
Ages Eligible for Study: | 2 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |||||
U.T.M.D. Anderson Cancer Center | |||||
Houston, Texas, United States, 77030 |
M.D. Anderson Cancer Center |
Celgene Corporation |
Principal Investigator: | Razelle Kurzrock, MD | U.T.M.D. Anderson Cancer Center |
Study ID Numbers: | 2004-0735 |
First Received: | July 2, 2007 |
Last Updated: | August 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00496444 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|